Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
about
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving ConceptsOutcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysisIdentification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of U.S.-based studies, 1996-2011.Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysisEarly and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysisPharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapyA randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomesAdherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South AfricaDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyHIV drug resistance early warning indicators in namibia with updated World Health Organization guidanceMonitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization RecommendationsProvider-Level and Other Health Systems Factors Influencing Engagement in HIV Care: A Qualitative Study of a Vulnerable PopulationAssessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in NamibiaHIV-1 Genetic Variability and Clinical ImplicationsDynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.Alcohol use, antiretroviral therapy adherence, and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus.Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection.Novel Approaches for Visualizing and Analyzing Dose-Timing Data from Electronic Drug Monitors, or "How the 'Broken Window' Theory Pertains to ART Adherence".Use of pharmacy refill data as a measure of antiretroviral adherence."That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme.Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these?The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis.Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic AnalysisAdherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy.Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, VietnamRandomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.Outcomes after virologic failure of first-line ART in South AfricaPrevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaPopulation-based monitoring of HIV drug resistance in Namibia with early warning indicators.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcomeIncomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings.Household food insecurity associated with antiretroviral therapy adherence among HIV-infected patients in Windhoek, NamibiaEvaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value?
P2860
Q22241321-C9499FE1-E737-46CA-AB86-8143BDBF7A22Q27021762-1CC5A274-5AEC-4868-90D2-C455AF58A12FQ27318276-75A5D4C2-ACBD-4719-AA3C-6192B236D19FQ28081677-6DE9A9B7-0516-4159-B5F0-E129DDC757FFQ28472043-26D08E94-94F6-44C9-9A8F-0765402D7C25Q28472810-1B520138-3D2B-47B5-B5B0-8FC99CED49E1Q28477310-D856FE20-94A5-4F30-BC28-E05F20F7A701Q28477379-5C20F5EB-3E07-40D8-A8B8-544C1F220D6AQ28478666-3716A4C9-F744-43D8-97B6-21CE5F771FD7Q28534423-8951EBAE-AA2E-45EA-98DA-F64340C9E7E3Q28540264-1BA431AB-7DE6-4AB8-ACEF-F8EF2A2D7E71Q28548432-A9B33934-E84E-4558-82D2-4952C4E56FCAQ28552668-C5816BDA-90BE-41B8-AC2B-43115CDDE58DQ28554721-356FF8C2-DEFF-4CC5-8629-30830CCB2F1AQ30352010-96D7BBEC-2797-44EF-B258-9FE4D3470306Q30558310-37371F91-F2D4-430B-A28E-E75DEFF361B1Q30575455-EB9A8B3C-5F40-4695-9267-8618E5277162Q30666487-0467DD1E-150E-4CF3-B998-75F794FD170BQ30936928-B295493C-C061-4BBC-AEB4-3115D0B22C48Q31150646-EE000C81-B669-4DFE-AD14-436E6CF2DD6BQ33320220-BDC66A59-F6CA-4CA4-AD0C-7809583D7882Q33355997-B97F279F-8844-45D5-A578-F84D1B780663Q33390354-E2AA9CF4-B659-4896-BEE0-7ABDE9F5D7A4Q33507274-D73ACA7D-168D-4152-BF49-6BB59CFE0665Q33582022-425BF773-65FC-48C9-9335-775130F190ADQ33611057-F3A4CE02-F008-4E58-8E50-6A9A8785E332Q33737122-A394EDB7-05B4-4F31-953B-EE868AA1162EQ33814942-8984BD54-992A-4025-A002-3466B882DE0DQ33869982-02C72F40-6365-45C7-BA39-D9F846A85EA8Q33921104-01B63ED8-05E5-4D1B-93F0-A5562FD25487Q33925552-17A121C8-5517-46C2-BB76-048908C51E61Q33952538-5DBDFC29-7907-4FCF-8F81-BBCD4A1AD8A5Q33985234-C5FE290C-A8CE-43D3-B687-AFDA3B3EF782Q34116836-6F4C877A-8E46-4085-8CD3-7B618C04D950Q34283361-72EF1803-549C-4EBE-9958-C49D3791163CQ34292437-293BF9CC-CE00-46A7-A761-B1F18F79FD73Q34324005-FAFB3677-C68E-48E0-8480-81619925CC94Q34325958-746B8984-9546-4A91-AF04-E829ABE8E99BQ34430645-8C1B2021-5021-40A3-AE55-4B1808D9CA78Q34546423-43F20679-F7BA-4EE1-B3E2-DD8328A50D5D
P2860
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@en
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@nl
type
label
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@en
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@nl
prefLabel
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@en
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@nl
P2093
P1476
Adherence to nonnucleoside rev ...... herapy and virologic outcomes.
@en
P2093
David W Dowdy
Gary Maartens
Jean B Nachega
Leon Regensberg
Michael Hislop
P304
P356
10.7326/0003-4819-146-8-200704170-00007
P407
P577
2007-04-01T00:00:00Z